TargetMol

Amifampridine phosphate

Product Code:
 
TAR-T4497L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T4497L-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4497L-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4497L-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Amifampridine is mainly used to treat many rare muscle diseases. In the United States, aminopyridine is being studied for the treatment of Lambert-Eaton myasmus syndrome (LEMS). Amifampridine is also used to treat many congenital myasthenia syndromes, particularly those with defects in choline acetyltransferase, downstream kinase 7, and any type of defects leading to "fast track" defects.
CAS:
446254-47-3
Formula:
C5H10N3O4P
Molecular Weight:
207.126
Purity:
0.98
SMILES:
OP(O)(O)=O.Nc1ccncc1N

References

Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrni? D, Shieh P, Vial C, Meisel A, Komoly S, Schoser B, Sivakumar K, So Y; LEMS Study Group. Amifampridine phosphate (Firdapse?) is Effective and Safe in A Phase 3 Clinical Trial in LEMS. Muscle Nerve. 2016 Feb 6. doi: 10.1002/mus.25070. [Epub ahead of print] PubMed PMID: 26852139. Haroldsen PE, Garovoy MR, Musson DG, Zhou H, Tsuruda L, Hanson B, O'Neill CA. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099. doi: 10.1002/prp2.99. Epub 2014 Dec 9. PubMed PMID: 25692017; PubMed Central PMCID: PMC4317230. Haroldsen PE, Musson DG, Hanson B, Quartel A, O'Neill CA. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults. Clin Ther. 2015 Jul 1;37(7):1555-63. doi: 10.1016/j.clinthera.2015.05.498. Epub 2015 Jun 20. PubMed PMID: 26101174. Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurol Ther. 2015 Dec;4(2):105-24. doi: 10.1007/s40120-015-0034-0. Epub 2015 Nov 2. PubMed PMID: 26525537; PubMed Central PMCID: PMC4685864.